Experience with the portacath
- 1 January 1988
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 6 (1), 57-63
- https://doi.org/10.1002/hon.2900060109
Abstract
Fifty Portacaths have been inserted in patients undergoing prolonged outpatient chemotherapy, most for haematological disease. Twenty-one are still working at a median duration of 12 months (range 1-27) and a further 15 were functioning normally at the time of the patients death (median survival 6 months). Four functioning Portacaths have been removed, three suspected of causing septicaemia and one believed erroneously to have occluded. Ten have ceased to function and nine of these have been removed. The causes of these failures are nearly all avoidable and are discussed in detail; many occurred early in our experience. With careful attention to detail and with management by trained and interested staff, the Portacath is a safe and reliable device for intermittent vascular access.Keywords
This publication has 12 references indexed in Scilit:
- Totally implantable vascular access for long term chemotherapy.BMJ, 1986
- Is repeated flushing of Hickman catheters necessary?BMJ, 1985
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- Totally implanted system for intravenous chemotherapy in patients with cancerAmerican Journal Of Medicine, 1982
- Prospective Evaluation of Central Venous Pressure (CVP) Catheters in a Large City-County HospitalAnnals of Surgery, 1982
- Two methods for improved venous access in acute leukemia patientsJAMA, 1981
- USE OF MODIFIED SUBCUTANEOUS RIGHT-ATRIAL CATHETER FOR VENOUS ACCESS IN LEUKÆMIC PATIENTSThe Lancet, 1980
- USE OF RIGHT ATRIAL CATHETER FOR PROLONGED IV SUPPORT IN CANCER-PATIENTS1980
- MODIFIED RIGHT ATRIAL CATHETER FOR ACCESS TO THE VENOUS SYSTEM IN MARROW TRANSPLANT RECIPIENTS1979